{"id":94382,"date":"2026-05-18T17:08:43","date_gmt":"2026-05-18T17:08:43","guid":{"rendered":"https:\/\/teeptrak.com\/pharmaceutical-fda-21-cfr-part-11-validation-2027\/"},"modified":"2026-05-18T17:08:45","modified_gmt":"2026-05-18T17:08:45","slug":"pharmaceutical-fda-21-cfr-part-11-validation-2027","status":"publish","type":"post","link":"https:\/\/teeptrak.com\/en\/pharmaceutical-fda-21-cfr-part-11-validation-2027\/","title":{"rendered":"Pharma FDA 21 CFR Part 11 validation 2027: GAMP 5, IQ\/OQ\/PQ, electronic records, data integrity"},"content":{"rendered":"
\nTL;DR \u2014 Pharma FDA 21 CFR Part 11 validation in 60 words<\/strong>
\nFDA 21 CFR Part 11 (1997) regulates electronic records + electronic signatures equivalent to paper. Validation methodology: GAMP 5 (5 software categories), IQ\/OQ\/PQ protocols, ALCOA+ data integrity principles. New FDA CSA (Computer Software Assurance) guidance 2022 replaces traditional CSV with risk-based approach. EU GMP Annex 11 international counterpart. Vendors: Werum PAS-X leader, Siemens Opcenter Pharma, Rockwell PharmaSuite.\n<\/div>\n

The pharmaceutical industry operates under the most demanding regulatory framework of any industrial sector, with FDA 21 CFR Part 11<\/strong> “Electronic Records; Electronic Signatures” (effective 1997) as the foundational US regulation for digital systems in regulated environments. Combined with FDA 21 CFR Parts 210\/211<\/strong> (cGMP for pharmaceuticals), ICH Q10<\/strong> (Pharmaceutical Quality System), EU GMP Annex 11<\/strong> (Computerised Systems, EU equivalent), and GAMP 5<\/strong> (Good Automated Manufacturing Practice, ISPE methodology), pharmaceutical MES validation represents the deepest software validation challenge across all industries. This guide details Part 11 requirements, GAMP 5 categorization, IQ\/OQ\/PQ validation methodology, ALCOA+ data integrity principles, new FDA Computer Software Assurance (CSA)<\/strong> guidance (September 2022), and leading vendors (Werum PAS-X, Siemens Opcenter Pharma, Rockwell PharmaSuite). Major US pharma operators: Pfizer, Johnson & Johnson, Merck (MSD), AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Amgen, Biogen, Regeneron.<\/p>\n

21 CFR Part 11 structure: 3 Subparts<\/h2>\n\n\n\n\n\n\n\n
Subpart<\/th>\nTitle<\/th>\nKey requirements<\/th>\n<\/tr>\n<\/thead>\n
A<\/td>\nGeneral Provisions<\/td>\n\u00a711.1 Scope (electronic records equivalent to paper records when meeting Part 11 requirements), \u00a711.2 Implementation (predicate rules still apply), \u00a711.3 Definitions<\/td>\n<\/tr>\n
B<\/td>\nElectronic Records<\/td>\n\u00a711.10 Controls for closed systems (validation, audit trail, system access limits, training), \u00a711.30 Controls for open systems (encryption + digital signatures), \u00a711.50 Signature manifestations (printed name, date\/time, meaning), \u00a711.70 Signature\/record linking<\/td>\n<\/tr>\n
C<\/td>\nElectronic Signatures<\/td>\n\u00a711.100 General requirements (uniqueness, identity verification), \u00a711.200 Electronic signature components (two distinct components for non-biometric), \u00a711.300 Controls for identification codes\/passwords<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a711.10 closed system requirements (most relevant for MES)<\/h2>\n

21 CFR \u00a711.10 specifies controls for closed systems (network within organizational control). MES typically operates as closed system. Requirements:<\/p>\n

    \n
  • (a) Validation<\/strong>: System validated to ensure accuracy, reliability, consistent intended performance, ability to discern invalid\/altered records<\/li>\n
  • (b) Copies of records<\/strong>: Generate accurate copies in both human-readable and electronic form for FDA inspection<\/li>\n
  • (c) Protection of records<\/strong>: Records protected to enable accurate and ready retrieval throughout retention period (typically minimum 1-2 years post product expiration)<\/li>\n
  • (d) System access<\/strong>: Limited to authorized individuals<\/li>\n
  • (e) Audit trail<\/strong>: Secure, computer-generated, time-stamped audit trails recording date\/time of operator entries and actions creating\/modifying\/deleting electronic records<\/li>\n
  • (f) Operational checks<\/strong>: Sequencing of steps and events as appropriate<\/li>\n
  • (g) Authority checks<\/strong>: Only authorized individuals can use system, electronically sign records, access operation<\/li>\n
  • (h) Device checks<\/strong>: Validity of source of data input or operational instruction<\/li>\n
  • (i) Education\/training<\/strong>: Personnel developing\/maintaining\/using electronic record systems have education, training, experience<\/li>\n
  • (j) Written policies<\/strong>: Hold individuals accountable for actions initiated under their electronic signatures<\/li>\n
  • (k) Documentation control<\/strong>: Use of appropriate controls over systems documentation (distribution, access, audit trail of changes)<\/li>\n<\/ul>\n

    GAMP 5 categorization: 5 software categories<\/h2>\n

    GAMP 5<\/strong> (Good Automated Manufacturing Practice, published by ISPE – International Society for Pharmaceutical Engineering, current 2nd edition 2022) provides risk-based validation methodology. Software categorized into 5 categories with proportionate validation effort:<\/p>\n\n\n\n\n\n\n\n\n\n
    Category<\/th>\nType<\/th>\nExamples<\/th>\nValidation approach<\/th>\n<\/tr>\n<\/thead>\n
    Category 1<\/strong><\/td>\nInfrastructure Software<\/td>\nOperating systems (Windows Server, RHEL), databases (Oracle, SQL Server), network components<\/td>\nConfiguration management, change control. No formal validation beyond infrastructure qualification<\/td>\n<\/tr>\n
    Category 2<\/strong><\/td>\nFirmware (deprecated in GAMP 5 v2)<\/td>\nNow merged into Category 3 or 4 depending on configurability<\/td>\nN\/A in current GAMP 5<\/td>\n<\/tr>\n
    Category 3<\/strong><\/td>\nNon-Configured Products<\/td>\nCommercial off-the-shelf (COTS) applications used out-of-the-box: standard reporting tools, simple HMI<\/td>\nRisk-based, minimal validation. Vendor audit + basic functional tests<\/td>\n<\/tr>\n
    Category 4<\/strong><\/td>\nConfigured Products<\/td>\nCOTS products configured for specific use: MES (Werum PAS-X, Siemens Opcenter Pharma), DMS, LIMS, SCADA configured<\/td>\nURS \u2192 FRS \u2192 DRS \u2192 Configuration \u2192 IQ \u2192 OQ \u2192 PQ. Most MES falls here<\/td>\n<\/tr>\n
    Category 5<\/strong><\/td>\nCustom Applications<\/td>\nBespoke developed code, custom scripts, custom integrations<\/td>\nFull lifecycle validation: URS, FRS, DRS, Design, Code Review, Unit Testing, Integration Testing, IQ\/OQ\/PQ<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Most pharmaceutical MES implementations fall into GAMP Category 4 (Configured Products)<\/strong>, with custom interfaces and integrations potentially Category 5.<\/p>\n

    \n

    Download the white paper<\/h3>

    Enter your email address to receive our White Paper<\/p> \n

    \n
    <\/div> \n
    \n